Search research articles

Search research articles

Related Experiment Videos

Treatments for stroke.

Isabel J Beresford¹, Andrew A Parsons, A Jacqueline Hunter

¹Neurology & GI Centre of Excellence for Drug Discovery, GlaxoSmithKline Research & Development Ltd, New Frontiers Science Park, Third Avenue, Harlow, Essex CM19 5AW, UK. isabel_j_beresford@gsk.com

Expert Opinion on Emerging Drugs

|November 13, 2003

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Identification of clinical candidates from the benzazepine class of histamine H3 receptor antagonists.

Bioorganic & medicinal chemistry letters·2013

Same author

The discovery of the benzazepine class of histamine H3 receptor antagonists.

Bioorganic & medicinal chemistry letters·2013

Same author

Proteomic identification and early validation of complement 1 inhibitor and pigment epithelium-derived factor: Two novel biomarkers of Alzheimer's disease in human plasma.

Proteomics. Clinical applications·2010

Same author

SB 234551 selective ET(A) receptor antagonism: perfusion/diffusion MRI used to define treatable stroke model, time to treatment and mechanism of protection.

Experimental neurology·2008

Same author

GSK189254, a novel H3 receptor antagonist that binds to histamine H3 receptors in Alzheimer's disease brain and improves cognitive performance in preclinical models.

The Journal of pharmacology and experimental therapeutics·2007

Same author

Identification of neuroprotective properties of anti-MAG antibody: a novel approach for the treatment of stroke?

Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism·2005

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Stroke treatments focus on improving blood flow, protecting brain tissue, and enhancing recovery. While neuroprotective agents show promise, acute treatments face time window limitations, highlighting the potential of recovery-focused interventions for stroke patients.

Area of Science:

Neurology
Clinical Trials
Pharmacology

Background:

Stroke is a leading cause of death and disability globally.
Current stroke treatments are limited in efficacy and accessibility.
There is a critical need for improved therapeutic strategies for stroke.

Purpose of the Study:

To review current and emerging stroke treatment approaches.
To focus on mechanisms with agents currently in clinical trials.
To explore strategies for acute treatment, neuroprotection, recovery, and recurrence reduction.

Main Methods:

Literature review of stroke treatment mechanisms.
Analysis of agents in Phase II and III clinical trials.
Discussion of therapeutic challenges and future directions.

Related Experiment Videos

Main Results:

Several neuroprotective agents are in advanced clinical trials.
Acute stroke treatments often have narrow therapeutic time windows.
Combination therapies present development challenges.
Stroke recovery promotion offers significant therapeutic potential.

Conclusions:

Optimizing acute stroke treatments requires addressing time window limitations.
Combination therapies may offer greater benefits but are complex to develop.
Promoting stroke recovery is a promising area for therapeutic intervention.
Preclinical research is identifying novel pathways for stroke recovery.